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Abstract
Introduction: The TWIST homolog 1 (TWIST1) is a transcription factor that induces epithelial to mesenchymal
transition (EMT), a key process in metastasis. The purpose of this study was to investigate whether TWIST1
expression predicts disease progression in a large breast cancer cohort with long-term clinical follow-up, and to
reveal the biology related to TWIST1 mediated disease progression.
Methods: TWIST1 mRNA expression level was analyzed by quantitative real-time reverse polymerase chain reaction
(RT-PCR) in 1,427 primary breast cancers. In uni- and multivariate analysis using Cox regression, TWIST1 mRNA
expression level was associated with metastasis-free survival (MFS), disease-free survival (DFS) and overall survival
(OS). Separate analyses in lymph node-negative patients (LNN, n = 778) who did not receive adjuvant systemic
therapy, before and after stratification into estrogen receptor (ER)-positive (n = 552) and ER-negative (n = 226)
disease, were also performed. The association of TWIST1 mRNA with survival endpoints was assessed using Kaplan-
Meier analysis. Using gene expression arrays, genes showing a significant Spearman rank correlation with TWIST1
were used to identify overrepresented Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes
(KEGG)-annotated biological pathways.
Results: Increased mRNA expression level of TWIST1 analyzed as a continuous variable in both uni- and
multivariate analysis was associated with shorter MFS in all patients (hazard ratio (HR): 1.17, 95% confidence
interval, (95% CI):1.09 to 1.26; and HR: 1.17, 95% CI: 1.08 to 1.26; respectively), in LNN patients (HR: 1.22, 95% CI: 1.09
to 1.36; and HR: 1.21, 95% CI: 1.07 to 1.36; respectively) and in the ER-positive subgroup of LNN patients (HR: 1.34,
95% CI: 1.17 to 1.53; and HR: 1.32, 95% CI: 1.14 to 1.53; respectively). Similarly, high TWIST1 expression was
associated with shorter DFS and OS in all patients and in the LNN/ER-positive subgroup. In contrast, no association
of TWIST1 mRNA expression with MFS, DFS or OS was observed in ER-negative patients. Genes highly correlated
with TWIST1 were significantly enriched for cell adhesion and ECM-related signaling pathways. Furthermore, TWIST1
mRNA was highly expressed in tumor stroma and positively related to tumor stromal content (P <0.001).
Conclusions: TWIST1 mRNA expression is an independent prognostic factor for poor prognosis in LNN/ER-positive
breast cancer. The biological associations suggest an involvement of the tumor microenvironment in TWIST1’s
adverse role in breast cancer.
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Introduction
Breast cancer is one of the most frequently diagnosed
cancers and the leading cause of cancer related deaths
among females of the Western world [1]. Patients do not
die from the primary tumor, but from metastases, which
already are resistant or acquire resistance to systemic
therapy. Metastasis is a complex, multi-step process in
which malignant cells undergo sequential molecular
changes helping them to disengage from primary sites,
intravasate into blood vessels, extravasate to distant
organs and finally colonize secondary sites. Each of these
metastatic steps is affected by aberrant expression of a
variety of transcription factors and among them, TWIST
homologue 1 (TWIST1) is considered an important regu-
lator of disease progression [2].
The TWIST1 protein, encoded by the TWIST1 gene, is
a member of a large protein family called basic helix-
loop-helix (bHLH) transcription factors [3]. Most family
members contain a bHLH domain, which enables it to
target specific DNA sequences and thereby allowing
them to regulate developmental processes in many
organs and tissues. TWIST1 plays a key role in the regu-
lation of embryogenesis, gastrulation and mesoderm for-
mation during early embryonic development of
Drosophila and many other species [4,5]. An autosomal
mutation pattern in the TWIST1 gene leads to Saethre-
Chotzen syndrome, a genetic condition characterized by
premature fusion of skull bones affecting symmetrical
growth of the head and face [6]. In children, TWIST1
protein is involved in adequate maturation of the skull
and spine bones and normal development of arms and
hind legs.
More recently, TWIST1 protein has been implicated in
various carcinomas, including breast cancer, where it
plays a role in metastasis through activation of a biologi-
cally latent developmental process called epithelial to
mesenchymal transition (EMT) [7,8]. In the EMT pro-
cess, malignant epithelial cells undergo cytoskeletal
changes, including the down-regulation of epithelial mar-
kers, such as E-cadherin and co-expressed catenins and
up-regulation of mesenchymal markers, such as vimen-
tin, N-cadherin and fibronectin. EMT transformed malig-
nant cells are more motile and can be more efficient in
invading the surrounding tissues and as a result metasta-
size to distant organs [9].
In this large retrospective study of 1,427 primary breast
cancer patients, we determined whether the TWIST1
gene expression level is a prognostic marker. To avoid
possible confounding effects of therapy and to study the
natural course of the disease, we particularly focused on
the subgroup of 778 lymph node-negative (LNN) patients
who did not receive any adjuvant systemic therapy. Addi-
tionally, to understand the biological context of TWIST1,
we have identified, using available Affymetrix U133A
gene expression data [10,11], genes and biological path-
ways co-expressed with TWIST1. By doing this, we iden-
tified a clear link between the tumor microenvironment
and TWIST1 expression in clinical breast cancer.
Methods
Patients
This study was approved by the institutional medical
ethics committee of the Erasmus MC (MEC 02.953). The
study was performed in accordance with the Code of Con-
duct of the Federation of Medical Scientific Societies in
The Netherlands [12]; informed consent was not required.
Wherever possible, the study has been reported in line
with the Reporting Recommendations for Tumor Marker
Prognostic Studies guidelines [13,14]. Breast cancer tissue
specimens from 1,427 female patients with primary oper-
able breast cancer were included in the study. Tumor sam-
ples were originally submitted to our reference laboratory
from 25 regional hospitals for biochemical assessment of
steroid hormone receptor status. Guidelines for primary
treatment were similar in all hospitals. All available frozen
breast tumor samples of at least 100 mg from female
patients with invasive breast cancer who entered the clinic
during the period of 1978 to 2001, and from whom
detailed clinical follow-up data were available were pro-
cessed. Moreover, these patients had no distant metastasis
within the first month after primary surgery and no prior
cancer except basal skin carcinoma and cervical cancer
stage I. ER, PGR and HER2 (ERBB2) levels were assessed
by quantitative real-time reverse transcriptase PCR (qRT-
PCR) as described before [15-17]. Lymph node involve-
ment, tumor size and grade were extracted from the
pathology reports as obtained from the hospitals. Primary
surgical treatment was lumpectomy in 628 patients (44%)
or modified mastectomy for 799 patients (56%). One thou-
sand and nine patients (71%) received adjuvant radiother-
apy at the thoracic wall only (n = 639) and either at the
thoracic wall and nodal stations (n = 290) or at the nodal
stations only (n = 80). Thirty-three percent of the patients
had T1 tumors. The median age of the patients at surgery
was 55 years (range, 23 to 89 years). Routine post-surgical
follow-up and the definition of the endpoints of MFS, DFS
and OS were described before [11,18]. During follow-up, a
local/regional relapse for 127 patients was not counted as
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an event in the analysis of MFS. The median follow-up
time was 104 months (range, 4 to 262 months) with 707
and 669 events in the analyses of MFS and OS, respec-
tively. Study design, patient inclusion criteria and patient
subgroups included in the analyses are given in Figure 1.
Other relevant clinico-pathological characteristics are
listed in Table 1.
Tissue processing and estimation of the amount of
epithelial tumor cells
Tissue processing was done as described in detail pre-
viously [15,19]. In brief, 20 to 60 cryostat sections of
30 µm size corresponding to 30 to 100 mg weight were
cut from frozen tissues. Three 5 µm sections were cut
before, in between and after cutting the sections for RNA
isolation, and were stained with hematoxylin and eosin
(H&E) to assess the amount of tumor cells relative to the
amount of surrounding stromal cells. The amount of
nuclei evidently of epithelial tumor cell origin relative to
the amount of surrounding stromal cells was estimated
with a 100-fold magnification in 10 different areas cover-
ing the area of each of the three H&E sections. Only speci-
mens with at least 30% of the nuclei of epithelial tumor
cell origin and distributed uniformly over at least 70% of
the section area were included. Like before [16], these esti-
mates were used to dichotomize our tumor cohort at the
Figure 1 Study design, patient inclusion criteria and patient sub-cohorts analyzed. Associations of TWIST1 mRNA expression levels with
tumor aggressiveness were evaluated in all patients and in LNN, LNN/ER-positive and LNN/ER-negative patients. The LNN patients in this study
did not receive adjuvant systemic therapy.
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median level of 70% tumor cell nuclei in stromal-rich (SR)
(primary tumors containing >30% stromal components)
and stromal-poor (SP) (primary tumors containing at least
70% tumor cells).
RNA isolation, cDNA synthesis, and quantification of
specific mRNA species
RNA isolation, cDNA synthesis, quantification of specific
mRNA species and quality control checks were done as
described previously by Sieuwerts et al. [15]. qRT-PCR
was performed in 25-µl reaction volume in a Mx3000P
Real-time PCR System (Agilent, Amsterdam, The Neth-
erlands) using a commercially available gene expression
assay for TWIST1 (Hs00361186_m1) and for VIM (Hs
Hs00185584_m1) from Applied Biosystems/Life Tech-
nologies (Nieuwerkerk aan den IJssel, The Netherlands).
For EPCAM mRNA measurement, a combination of the
following primers and probe was used (F: 3’-AGT TTG
CGG ACT GCA CTT CA, R: 3’- AAT ACT CGT GAT
AAA TTT TGG ATC CA, FAM-labeled MGB probe:
Table 1 Association of TWIST1 mRNA expression with standard clinical and pathological characteristics of patients and
tumors
Characteristics No. patients TWIST1 mRNA expression (Median value*) P-value
Age (years)
<40 188 0.025
41 to 55 530 0.028
56 to 70 471 0.030
>70 238 0.020 0.04†
Menopausal status
Premenopausal 603 0.027
Postmenopausal 824 0.027 0.21‡
Tumor size
pT1, <2 cm 463 0.031
pT2, >2 to <5 807 0.025
pT3, >5 + pT4 157 0.028 0.009¶
Lymph nodes involved
0 778 0.026
1 to 3 288 0.025




Unknown 397 0.029 0.47¶
Tumor histology
IDC 957 0.027
ILC 112 0.044 <0.001‡, §
Medullary 31 0.016
Mucinous 39 0.008 <0.001¶
ER status (mRNA)
Negative 360 0.021
Positive 1,067 0.029 0.06†
PGR status (mRNA)
Negative 572 0.023
Positive 855 0.029 <0.001†
ERBB2 status (mRNA)
Negative 1,187 0.026
Positive 240 0.032 <0.001†
Abbreviations: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
* Expression values after normalization to our set of three reference genes (B2M, HMBS and HPRT1).
† P Spearman rank correlation test.
‡ P for Mann-Whitney test.
¶ P for Kruskal-Wallis test.
§ TWIST1 expression was compared between IDC and ILC tumors.
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AAG GAG ATC ACA ACG CGT). Primer sequences for
estrogen receptor-a (ESR1), progesterone receptor
(PGR), ERBB2 and the reference genes (HMBS, HPRT1
and B2M), as well as how PCR reactions and validations
were carried out to ensure PCR specificity, were done as
described before [15,17]. Levels of mRNA expression
were quantified relative to the set of reference genes as
described before [15].
Laser capture microdissection
Laser capture microdissection (LCM) was performed
according to a previously published method [20]. Briefly, 8
µm sections of fresh frozen tumor tissue were cryosec-
tioned and pasted on UV sterilized polyethylene naphtha-
late (PEN) covered glass slides (P.A.L.M. Microlaser
Technologies, Bernried, Germany). The slides were air
dried for 10 sec at room temperature, fixed in ice-cold
70% ethanol and washed shortly in Milli-Q water. The
slides were then stained for 15 sec in Haematoxylin (Klini-
path 4085.9005, Duiven, The Netherlands) and washed
again in Milli-Q water. Subsequently, the slides were dehy-
drated twice in RNase-free 50, 70, 95 and 100% ethanol for
30 sec each, and air-dried. Next, LCM was performed
directly on the stained sections. From consecutive cryosec-
tions of a tumor tissue, both the stromal content and
tumor epithelial cells were collected separately in triplicate
in P.A.L.M. tube caps containing 25 μl of tissue lysis (RLT
+) buffer (Qiagen 1053393, Venlo, The Netherlands) using
a P.A.L.M. LCM device, type P-MB (P.A.L.M. Microlaser
Technologies AG). Both stromal and epithelial cell frac-
tions were then spun down into 0.5-ml Eppendorf Protein
LoBind tubes (Eppendorf, Hamburg, Germany) containing
225 μl RLT+ buffer and used for RNA isolation.
Immunohistochemistry (IHC)
Sections of 4 µm were cut from formalin-fixed paraffin-
embedded tissues, pasted on glass slides and dried over-
night at 37°C. The slides were dewaxed in xylene solution
and hydrated in a series of different percentages of
alcohol (100%, 95%, 75% and 50%). The antigen was
retrieved for 40 minutes in a hot water bath (at 95°C ) in
Tris-EDTA buffer, pH 9.0 (DAKO; S2367, Glostrup,
Denmark) and cooled for 20 minutes at room tempera-
ture. After retrieval, slides were immersed in 3% hydro-
gen peroxide for 10 minutes to block endogenous
peroxidase activity, and in a DAKO protein-free serum
blocking solution for 30 minutes to block non-specific
binding sites. The slides were then incubated overnight
at 4°C with a mouse monoclonal primary antibody raised
against a human recombinant fragment of TWIST1
(AbCam TWIST2C1a, ab50887, Cambridge, UK) and
diluted 1:100 in an antibody diluent (DAKO). Negative
controls were made by replacing the primary antibody
with mouse immunoglobulin at an appropriate dilution.
Next, the slides were treated with a secondary antibody
(envision mouse kit, DAKO) and visualized using DAB
(envision kit, DAKO). The slides were counterstained
with hematoxylin and dehydrated through graded alcohol
and xylene. Evaluation of the immunostaining and histos-
coring were performed according to a previously pub-
lished method [21]. Briefly, a histoscore of 0 to 300 was
given to each tumor by multiplying the proportion of
cells with nuclear staining in a tissue by the intensity of
the staining as follows; histoscore = (0 × percentage not
stained) + (1 × percentage weakly stained) + (2 × percen-
tage moderately stained) + (3 × percentage strongly
stained). The histoscores calculated in this way were cor-
related with TWIST1 mRNA expression. The intensity of
TWIST1 stromal expression in tumor tissues was scored
as no, weak, moderate or strong staining.
Identification of TWIST1 co-expressed genes on
Affymetrix U133A gene-chips and identification of Gene
Ontology (GO) terms and biological pathways
In this analysis we used TWIST1 mRNA expression,
which was previously measured by Affymetrix U133A
gene-chips (Affymetrix, Santa Clara, CA, USA) (probe set
213943_at) [10,11,22]. The mRNA expression levels of
TWIST1 measured on the Affymetrix-array and by qRT-
PCR were highly correlated in an overlap of 193 LNN/
ER-positive and 118 LNN/ER-negative tumor specimens
using the Spearman-Rank correlation test (Spearman
rank correlation, Rs = 0.7; P <0.001 for both). Genes
showing a significant positive or negative correlation
with TWIST1 were identified by using these Affymetrix-
array data after all genes were corrected for multiple test-
ing by applying a false discovery rate (FDR) of 5% [23].
Biological pathways and GO terms from genes signifi-
cantly co-expressed with TWIST1 were identified using
the ArrayTrack™software (NCTR/FDA, Jefferson, AR
72079, USA) [24]. The overrepresented pathways and
GO terms identified by ArrayTrack™ were based on
Fisher’s exact statistics. Details about how ArrayTrack™
software functions can be retrieved from the website
[25]. The gene expression data used have previously been
deposited in the National Center for Biotechnology Infor-
mation/Gene Expression Omnibus database entries
GSE2034 and GSE5327.
Statistics
Computations were done with the use of the STATA
statistical package, release 11.2 (STATA Corp., College
Station, TX, USA). Differences in levels were assessed with
the Mann-Whitney U test or Kruskal-Wallis test. In these
tests, patient and tumor characteristics were used as
grouping variables. The strengths of the associations
between continuous variables were tested with the Spear-
man rank correlation test. TWIST1 mRNA expression
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levels measured by qRT-PCR were log transformed to
reduce the skewness (Skewness-Kurtosis normality test,
P <0.05) and to attain symmetric distribution (Additional
file 1: Figure S1). The prognostic value of the clinical and
biological variables, with MFS, OS and DFS as the end
points in the univariate and multivariate analyses, were
investigated with the use of the Cox proportional hazard
model. The hazard ratio (HR) and its 95% confidence
interval (95% CI) were derived from these models by ana-
lyzing TWIST1 mRNA expression levels as a continuous
variable or after dividing their levels into quartiles. The
proportionality assumption was investigated with a test
based on the Schoenfeld residuals. Kaplan-Meier survival
analysis was performed and a log-rank test was used to
assess a trend of survivor’s function across four quartiles
of TWIST1 mRNA expression levels. All P-values are two-
sided, and P <0.05 was considered statistically significant.
Results
Association of TWIST1 mRNA expression with standard
clinical and pathological characteristics of patients and
tumors
Association of TWIST1 mRNA expression levels with
clinical and pathological characteristics of patients and
tumors are shown in Table 1. Tumor TWIST1 mRNA
expression was higher in patients with >3 positive lymph
nodes, and lower in pT2 tumors and in older patients.
Furthermore, TWIST1 mRNA expression was higher in
invasive lobular carcinoma (ILC) compared with invasive
ductal carcinoma (IDC). Mucinous and medullary-type of
tumors showed the lowest TWIST1 mRNA expression
levels. In addition, TWIST1 mRNA expression level was
higher in PGR-positive and ERBB2-overexpressing
tumors, but was not associated with tumor grade and
menopausal status.
Association of TWIST1 mRNA expression with prognosis in
primary breast cancer patients
To explore the prognostic significance of TWIST1
mRNA expression in primary breast cancer patients,
we first performed Cox uni- and multivariate analyses
(traditional factors in the multivariate analysis were;
age, menopausal status, number of positive lymph
nodes, tumor size, tumor grade, ER status, PGR status
and ERBB2 status) for MFS, DFS and OS as a function
of continuous TWIST1 mRNA expression levels. In all
1,427 patients, increasing TWIST1 mRNA expression
levels was associated with shorter MFS in both uni-
and multivariate analysis (HR: 1.17, 95% CI: 1.09 to
1.26; P <0.001 and HR: 1.17, 95% CI: 1.08 to 1.26;
P <0.001; respectively) (Table 2). To visualize the prog-
nostic value of TWIST1 mRNA expression in Kaplan-
Meier survival curves, we divided TWIST1 expression
levels into four quartiles Q1 (low) to Q4 (high) (Figure 2).
To exclude a possible confounding treatment effect, we
also evaluated the prognostic value of TWIST1 mRNA
expression in LNN-patients who did not receive any adju-
vant systemic therapy. We also stratified these LNN
patients into ER-positive and ER-negative subgroups as
these subgroups are considered biologically distinct. In the
analysis of all 778 LNN patients, an association of increas-
ing TWIST1 mRNA expression levels with shorter MFS
was observed in both uni- and multivariate analysis (uni-
variate HR: 1.22, 95% CI: 1.09 to 1.36; P = 0.001 and HR:
1.21, 95% CI: 1.07 to 1.36; P = 0.001; respectively) (Addi-
tional file 2: Table S1). Moreover, within the LNN sub-
group of patients, the association of increasing TWIST1
mRNA levels with shorter MFS was confined to the ER-
positive subgroup of patients (univariate (HR: 1.34, 95%
CI: 1.17 to 1.53; P <0.001) and multivariate (HR: 1.32, 95%
CI: 1.14 to 1.53; P <0.001)) (Table 3). There was no asso-
ciation of TWIST1 mRNA levels with MFS in the ER-
negative subgroup of patients (univariate HR = 1.05, 95%
CI: 0.86 to 1.29; P = 0.64) (Additional file 2: Table S2).
Kaplan-Meier survival curves for all patients and sub-
groups of patients with LNN and LNN/ER-positive and
LNN/ER-negative disease, after dividing these cohorts in
quartiles (Q1 to Q4), are shown in Figure 2A-D. Cox
regression analysis for MFS showed that in the LNN/ER-
positive group the quartile with the highest TWIST1
mRNA levels (Q4) had a two-fold increased hazard ratio
compared with the quartile with the lowest TWIST1
mRNA levels (Q1) (Table 3).
We also related TWIST1 mRNA expression levels with
OS in all patients, in the LNN cases as a whole and after
stratifying by ER status. Similarly as observed for MFS,
increasing TWIST1 mRNA expression levels was asso-
ciated with shorter OS in all patients (univariate HR:
1.10, 95% CI: 1.08 to 1.26, P = 0.013; multivariate HR:
1.11, 95% CI: 1.03 to 1.20, P = 0.006), in the LNN (uni-
variate HR: 1.13, 95% CI: 1.01 to 1.27, P = 0.03; multivari-
ate HR: 1.16, 95% CI: 1.03 to 1.30, P = 0.01) and in the
LNN/ER-positive group of patients (univariate HR: 1.26,
95% CI: 1.09 to 1.45, P = 0.001; multivariate HR: 1.27,
95% CI: 1.11 to 1.46, P = 0.001). These associations were
not significant in the LNN/ER-negative group of patients
(univariate HR: 0.96, 95% CI: 0.78 to 1.18, P = 0.69; mul-
tivariate HR: 0.98, 95% CI: 0.79 to 1.21, P = 0.85). The
results are included in Additional file 2: Tables S3-S6.
Kaplan-Meier survival curves showing OS for all patients,
and also for the subgroups of patients after dividing them
into quartiles based on TWIST1 mRNA levels are shown
in Additional file 1: Figure S2A-D.
We finally analyzed whether TWIST1 mRNA expres-
sion levels were associated with DFS in all patients and
in LNN/ER-positive patients only, and obtained similar
results as were obtained for MFS and OS (Additional
file 2: Tables S7-8).
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Investigation of TWIST1 related biological pathways in
LNN breast cancer
To explore the underlying biology of TWIST1-associated
disease progression in breast cancer, we determined
TWIST1 co-expressed genes previously measured on Affy-
metrix U133A gene-chips [10,11]. Since we found TWIST1
to be associated with poor prognosis in LNN/ER-positive
patients only, we first decided to include only the LNN/
ER-positive samples to examine the TWIST1 co-expressed
genes. After using a Spearman correlation test followed by
applying a multiple testing correction at a FDR of 5%, we
found 1,847 genes to be positively correlated and 1,445
genes to be negatively correlated with TWIST1 mRNA
expression (Additional file 3: Table S9A, B). To reveal
which biological pathways might be associated with
TWIST1 mRNA expression, we performed pathway ana-
lyses using the genes co-expressed with TWIST1 and the
KEGG pathway database as input for the analysis in the
ArrayTrack™ software package. The three most signifi-
cantly overrepresented pathways containing these TWIST1
co-expressed genes were: Focal adhesion pathway (Fisher’s
exact P = 1.0 × 10-8), ECM-receptor interaction pathway
Table 2 Model for uni-and multivariate analysis for metastasis-free survival in all patients (n = 1,427)
Factors No. patients Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Age (years)
<40 188 1 1
41 to 55 530 0.92 0.73 to 1.16 0.47 0.88 0.69 to 1.12 0.30
56 to 70 471 1.02 0.80 to 1.29 0.88 0.85 0.59 to 1.21 0.36
>70 238 0.80 0.66 to 1.06 0.12 0.69 0.47 to 1.03 0.07
Menopausal status
Premenopausal 603 1 1
Postmenopausal 824 1.07 0.92 to 1.25 0.35 1.23 0.94 to 1.62 0.14
Tumor size
pT1, <2 cm 463 1 1
pT2, >2 to <5 807 1.65 1.39 to 1.97 <0.001 1.38 1.15 to 1.65 <0.001
pT3, >5 + pT4 157 2.80 2.20 to 3.58 <0.001 1.80 1.39 to 2.33 <0.001
Lymph nodes involved
0 778 1 1
1 to 3 288 1.79 1.48 to 2.17 <0.001 1.71 1.41 to 2.08 <0.001
>3 361 2.92 2.46 to 3.46 <0.001 2.63 2.19 to 3.16 <0.001
Grade
Poor 800 1 1
Good/Moderate 230 0.51 0.40 to 0.65 <0.001 0.64 0.50 to 0.82 <0.001
Unknown 397 0.89 0.75 to 1.05 0.17 0.99 0.83 to 1.17 0.87
ER status (mRNA)
Negative 360 1 1
Positive 1,067 0.82 0.70 to 0.97 0.02 0.83 0.67 to 1.04 <0.001
PGR status (mRNA)
Negative 572 1 1
Positive 855 0.75 0.64 to 0.87 <0.001 0.87 0.71 to 1.06 0.17
ERBB2 status (mRNA)
Negative 1,187 1 1
Positive 240 1.30 1.08 to 1.57 0.006 1.18 0.97 to 1.43 0.09
Addition to the base model
TWIST1 mRNA level† (Continuous) 1,427 1.17 1.09 to 1.26 <0.001 1.17 1.08 to 1.26 <0.001
TWIST1 mRNA level†
TWIST1 quartile 1 360 1 1
TWIST1 quartile 2 355 1.16 0.94 to 1.45 0.17 1.09 0.88 to 1.37 0.43
TWIST1 quartile 3 357 1.22 0.98 to 1.51 0.08 1.25 1.00 to 1.56 0.05
TWIST1 quartile 4 355 1.49 1.20 to 1.83 <0.001 1.43 1.15 to 1.77 0.001
†TWIST1 mRNA expression level (log-transformed after normalization to the expression of three reference genes) was separately added to the base multivariate
model that included the factors age, menopausal status, tumor size, grade, lymph-node status, ER, PGR, and ERBB2 mRNA expression levels, tested both as a
continuous variable and in four quartiles.
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(Fisher’s exact P = 9.9 × 10-7), and TGF-beta signaling
pathway (Fisher’s exact P = 2.6 × 10-4) (Additional file 3:
Table S10). In addition, GO term enrichments among
TWIST1 co-expressed genes identified “cell adhesion”,
“extracellular structure organization” and “anatomical
structure formation involved in morphogenesis” as the top
three significant GO terms (level >3; gene hits >5; P-values
<0.001) in the category of “biological processes”, and the
GO terms, “extracellular matrix” proteinaceous extracellu-
lar matrix and “extracellular matrix part” as the top three
significant GO terms in the category “protein cellular com-
ponents” (Additional file 3: Table S11).
To evaluate a possible TWIST1 mediated biological dif-
ference between LNN/ER-positive and LNN/ER-negative
patients, we also performed pathway analyses using
TWIST1 co-expressed genes (n = 1,141 positively and n =
498 negatively correlated genes with TWIST1, respectively,
Additional file 3: Table S12A, B) measured on Affymetrix
arrays from LNN/ER-negative patients (n = 118). As
observed in LNN/ER-positive patients, these analyses iden-
tified Focal adhesion and ECM-receptor interaction
pathways as the two most significant pathways. But, in
contrary to what observed in LNN/ER-positive patients,
the TGF-beta signaling pathway was not found to be the
Figure 2 Kaplan-Meier survival curves presenting the association of TWIST1 mRNA expression with metastasis-free survival in: A:
all 1,427 patients; B: LNN patients only, C: LNN and ER-positive patients and D: LNN and ER-negative patients. The LNN patients in this
study did not receive adjuvant systemic therapy. The patients are divided into four quartiles (Q1 (low) to Q4 (high)) based on TWIST1 mRNA
expression levels after normalizing these to the expression of our set of three reference genes (B2M, HMBS and HPRT1). Patients at risk at various
time points are indicated.
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third most significant pathway in LNN/ER-negative
patients (Additional file 3: Table S13). We also performed
pathway analysis using TWIST1 co-expressed genes in all
LNN patients irrespective of ER status. Analyses revealed
only Focal adhesion and ECM-receptor interaction path-
ways as the two most significant pathways, but the TGF-
beta signaling pathway was not found to be the third top
significant pathway in all patients (Additional file 3: Table
S14). Altogether, these data suggest that the co-expression
of the TGF-beta signaling pathway with TWIST1 gene is
more prominent in LNN/ER-positive cancer.
Association of TWIST1 mRNA expression levels with
stromal content
The co-expression analysis suggested an association
between stromal content of the tumor tissue and TWIST1
mRNA expression levels. Therefore, we studied the
association of TWIST1 mRNA expression with tumor
stromal content in more detail. For this, we performed
LCM to separately isolate the stromal (S) and epithelial
tumor cell (T) areas from 10 breast tumor tissues (n = 9
ESR1 high, n = 1 ESR1 low) with sufficiently micro-dissec-
tible fresh frozen tissue left. After LCM we measured
TWIST1 mRNA by qRT-PCR in RNA isolated from both
the stromal and the epithelial tumor cell fractions of these
tissues, and normalized the expression levels to our set of
reference genes. To ensure that our reference gene-set did
not cause a bias in these analyses, and our LCM material
was indeed enriched for stromal and epithelial cells, we
also measured VIM and EpCAM (Epithelial Cell Adhesion
Molecule) in these fractions (Figure 3A). In these analyses,
EpCAM mRNA expression was high in the epithelial
tumor cell fractions (3.4-fold, two-sided paired t-test P =
0.006) and VIM and TWIST1 mRNA expression were
Table 3 Model of uni- and multivariate analysis for metastasis-free survival in lymph-node negative and ER-positive
patients (n = 552)
Factors No. patients Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Age (years)
<40 66 1 1
41 to 55 187 0.97 0.64 to 1.49 0.90 1.05 0.68 to 1.64 0.81
56 to 70 179 0.79 0.51 to 1.23 0.29 0.81 0.40 to 1.66 0.57
>70 120 0.59 0.35 to 0.99 0.05 0.59 0.27 to 1.28 0.18
Menopausal status
Premenopausal 215 1 1
Postmenopausal 337 0.76 0.57 to 1.00 0.05 0.99 0.56 to 1.74 0.98
Tumor size
pT1, <2 cm 251 1 1
pT2, >2 to <5 276 1.12 0.84 to 1.49 0.43 1.09 0.82 to 1.46 0.34
pT3, >5 + pT4 25 1.62 0.84 to 3.11 0.15 1.92 0.99 to 3.75 0.06
Grade
Poor 257 1 1
Good/Moderate 124 0.53 0.35 to 0.79 0.002 0.56 0.37 to 0.85 0.007
Unknown 171 1.06 0.78 to 1.44 0.70 1.20 0.87 to 1.64 0.26
PGR status (mRNA)
Negative 116 1 1
Positive 436 0.67 0.49 to 0.92 0.013 0.71 0.51 to 0.99 0.04
ERBB2 status (mRNA)
Negative 475 1 1
Positive 77 1.51 1.06 to 2.15 0.02 1.39 0.97 to 2.00 0.08
Addition to the base model
TWIST1 mRNA level† (Continuous) 552 1.34 1.17 to 1.53 <0.001 1.32 1.14 to 1.53 <0.001
TWIST1 mRNA level†
TWIST1 quartile 1 135 1 1
TWIST1 quartile 2 125 1.02 0.65 to 1.61 0.92 0.90 0.57 to 1.43 0.67
TWIST1 quartile 3 149 1.28 0.85 to 1.94 0.24 1.09 0.71 to 1.68 0.70
TWIST1 quartile 4 143 2.06 1.39 to 3.04 <0.001 1.87 1.25 to 2.80 0.002
† TWIST1 mRNA expression level (log-transformed after normalization to the expression of three reference genes) was separately added to base multivariate
model that included the factors age, menopausal status, tumor size, grade, ER, PGR, and ERBB2 mRNA expression levels, tested both as a continuous variable and
in four quartiles.
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high in the stromal fractions (23.4-fold, P = 0.0001 and
14.6-fold, P = 0.0004, respectively). As the prognostic
value for TWIST1 mRNA expression is confined to ER-
positive breast cancer, we assessed whether ER expression
might be of relevance for TWIST1 mRNA expression in
tumor tissues with a variable amount of stromal content.
For this, we compared TWIST1 mRNA expression levels
between stromal rich (SR) and stromal poor (SP) tumors
in the ER-positive and ER-negative subgroups. Notably,
only in ER-positive tumors, TWIST1 mRNA expression
was significantly higher in SR compared with SP tumors
(Figure 3B, P <0.001); in ER-negative tumors the difference
was not significant (Figure 3C, P = 0.41).
This altogether suggests that TWIST1 mRNA is predo-
minantly expressed in the stromal compartment of breast
tumor tissues. Besides addressing the issue of where
TWIST1 mRNA is predominantly expressed in breast
cancer tissues as described above, we also performed
IHC staining to ascertain the localization of TWIST1
protein. For this, we stained 20 tumor tissues with differ-
ent TWIST1 mRNA expression (n = 10 with high
TWIST1 mRNA expression, n = 10 with low TWIST1
Figure 3 Association of TWIST1 mRNA expression with stromal content of the tumor tissue. A: TWIST1 mRNA expression levels in laser
capture microdissected breast tumor tissues. The stromal and epithelial tumor cell areas were separately analyzed after microdissecting 10 breast
tumor tissues (n = 9 with high ESR1expression, n = 1, (T6), with low ESR1 expression). After LCM, RNA isolation and cDNA synthesis were done as
described in the Patients and Methods sections. TWIST1 mRNA levels were measured by qRT-PCR in RNA isolated from both the stromal (S) and
the epithelial tumor cell (T) compartments of these tissues, and levels were normalized to our set of reference genes by the delta (Δ) Ct method.
To ensure our set of reference genes did not cause a bias in these analyses, and our LCM material was indeed enriched for stromal and
epithelial cells, we also measured VIM and EpCAM in these fractions. A two-sided paired t-test was performed to evaluate the differences. B:
TWIST1 mRNA expression in SR and SP ER-positive tumors and C: TWIST1 mRNA expression in SR- and SP ER-negative tumors. For figure sections
B and C, the mRNA expression of TWIST1 was log-transformed and the expression relative to reference genes is presented on the y-axis of the
box-and-whisker plots. The box-plot shows the five statistics (box bottom-line is the 25th percentile, solid line in the middle of the box presents
the median, upper line of the box is the 75th percentile and the whiskers extend to 1.5 times the inter-quartile range, observations beyond these
values are plotted, separately). Mann-Whitney test was performed to evaluate the difference between the SR and the SP groups in both ER-
positive and ER-negative patients (B, C).
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mRNA expression). Apparently, TWIST1 protein is pre-
dominantly localized in the nuclei of both epithelial
tumor cells and in almost all non-epithelial cells present
in the stromal compartment of tissues, such as fibroblast
cells, endothelial cells and inflammatory cells (Figure 4A,
B). In these 20 tumors, TWIST1 mRNA expression levels
were significantly correlated with the nuclear protein
expression in tumor tissue (Spearman rank correlation,
Rs = 0.61, P <0.004) (Figure 4C). Additionally, tumor tis-
sues showing weak/moderate TWIST1 protein staining
were mostly ER-negative (Figure 4C).
Our data suggest that stroma of ER-positive (and not
ER-negative tumors) is enriched for TWIST1. To address
this in more detail, we stained 20 primary breast tumor
tissues (n = 7 ER-negative and n = 13 ER-positive) for
TWIST1 protein. We observed that 2 out of 7 (29%) of
the ER-negative tumor tissues and 10 out of 13 (77%) of
the ER-positive tumor tissues showed moderate to strong
TWIST1 protein staining in the stroma. The staining of
TWIST1 in the other tumors (71% of the ER-negatives
and 23% of the ER-positives) was weak. These data based
on a limited number of samples further support our
qRT-PCR based findings at the protein level that the
Figure 4 Representative tissues with IHC staining of TWIST1 protein. A: Strong nuclear staining of TWIST1 protein in an ER-positive tumor
tissue with high TWIST1 mRNA expression. B: Weak nuclear staining of TWIST1 protein in an ER-negative tumor tissue with low TWIST1 mRNA
expression. C: Correlation of TWIST1 mRNA expression and protein expression in breast tumor tissues (n = 20; n = 10 high TWIST1 mRNA
expression, n = 10 low TWIST1 mRNA expression). Red and green boxes represent high and low TWIST1 mRNA expressing tumor tissues,
respectively, whereas empty boxes and filled boxes represent ER-negative and ER-positive tumor tissues, respectively. Spearman rank correlation
test was used to evaluate the correlation between TWIST1 mRNA and protein expression. D: Association of stromal staining of TWIST1protein
with ER-positive tumor tissues. (▽ = negative nuclei of inflammatory cells; ▼ = strong positive nuclei of inflammatory cells; ↕ = strong positive
nuclei of fibroblast; ⇨ = strong positive nuclei of tumor cells; ↓ = strong positive nuclei of endothelial cells).
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stroma of ER positive tumors is enriched for TWIST1
expression (Figure 4D).
Discussion
The bHLH transcription factor TWIST1, which is essen-
tial in developmental processes, such as gastrulation, has
been shown to be oncogenic in various cancers [26-33].
Functional studies pin-pointed a pivotal role for this pro-
tein in EMT, a fundamental biological process considered
to be crucial for metastatic spread in various carcinomas,
including breast cancer. This prompted us to analyze
mRNA expression of this gene in primary breast tumors
from a large retrospective cohort of patients with com-
plete clinical follow-up and address two basic questions.
First, can TWIST1 mRNA expression in breast cancer tis-
sue predict disease progression? Second, as we had Affy-
metrix U133A gene-chips data available for a subset of
samples [10,11,22], can we reveal which biological path-
ways are co-expressed with TWIST1 in breast cancer?
Our current study shows that high TWIST1 mRNA
expression is an independent marker of poor outcome in
breast cancer patients. As TWIST1 mRNA expression was
also a predictor of poor outcome in patients with LNN
disease who did not receive any adjuvant systemic treat-
ment, we may conclude that TWIST1 mRNA expression is
a pure prognostic marker and is associated with the nat-
ural course of disease progression. This suggests that
tumors with high expression of TWIST1 are more aggres-
sive, a finding that fits with experimental data where over-
expression of TWIST1 resulted in increased extravasation
during the dissemination of tumor cells [7]. Also in line
with this is the increased lymph node involvement of
breast tumors exhibiting higher TWIST1 expression as
observed by us and others [34]. The first seminal paper on
TWIST1 in breast cancer also showed higher TWIST1
mRNA expression in infiltrative lobular carcinoma [7],
which we also confirmed, though the implications of this
remain unclear.
What we further unexpectedly observed was that the
association of TWIST1 expression with poor prognosis
was confined to ER-positive cases and not seen in ER-
negative breast cancer. Similar observations were recently
made by Van Nes and colleagues [21]. This group, by
studying TWIST1 expression in a smaller-sized cohort
using IHC on tissue microarrays, also found significantly
more cumulative relapses in the ER-positive subgroup of
tumors. This observation was not significant in their entire
cohort, which also included ER-negative cases. Using the
same antibody, we observed, in a subset of formalin-fixed
specimen available from our cohort, clear nuclear
TWIST1 expression. This protein expression was not only
confined to the nuclei of invasive tumor cells but also pre-
sent in nuclei of other cells, such as fat cells, fibroblasts,
endothelial cells and inflammatory cells. Furthermore,
although based on small numbers, TWIST1 protein stain-
ing was high in those specimens in which we had mea-
sured high TWIST1 mRNA expression in a matched
fresh-frozen sample of the same tumor, while in speci-
mens with low TWIST1 mRNA expression the protein
staining was overall weaker or absent.
To study the potential biological mechanisms in disease
progression connected to TWIST1 expression, we identi-
fied genes co-expressed with TWIST1 in LNN/ER-posi-
tive tumors from which genome wide gene expression
data were available. Three related pathways were
revealed. The first pathway was “Focal adhesion”, which
involves interaction of ECM with integrin-A and -B
ligands. The second pathway, “ECM-receptor interac-
tion”, is related to ECM and involves collagen, laminin,
fibronetic, tenascin and integrin-A and -B proteins. The
third pathway is the “TGF-beta signaling”. How these
pathways, involving well-known cancer-related genes, are
connected to TWIST1 expression in relation to disease
progression in LNN/ER-positive cancer warrants func-
tional validation. A common denominator among these
three pathways, however, is their involvement in ECM
remodeling. There is a growing body of evidence showing
that changes in the tumor microenvironment can pro-
mote proliferation of the tumor cells and, therefore, can
influence outcome of patients [35], and our data connect
this to TWIST1 expression. Furthermore, our work also
shows that the stroma is a significant source of TWIST
transcript expression. Indeed, the current data reinforce
recent observations made by Roman-Perez and collea-
gues after evaluating gene expression patterns in 72
breast tissue samples [36]. They identified two distinct
subtypes, Active and Inactive, in the cancer-adjacent
extra-tumoral microenvironment of breast tissues and
demonstrated that TWIST1 was highly expressed along
with other stromal associated genes, such as VIM,
ADAMTS2, COL4A2, COL4A1, ITGA7 and ITGB1, in the
Active subtype. This could suggest a potential involve-
ment of TWIST1 in the activation of stroma in malignant
breast tissue. Furthermore, the Active subtype was asso-
ciated with expression of TGF-beta induced fibroblast
activation signatures, and showed a strong association
with OS among specifically ER-positive patients. Intrigu-
ingly, also in our data set, the association of TWIST1
with the TGF-beta signaling pathway appears to be more
prominent in ER-positive tumors.
Another recent study also demonstrated that TWIST1
protein can be found in both compartments of malig-
nant breast tissue, with a predominant expression in the
stromal compartment [37]. More importantly, they
found that, although rare in their hands, nuclear expres-
sion of TWIST1 protein in the epithelial tumor cell
compartment to be associated with poor prognosis (OS).
TWIST1 protein expression in the stromal compartment
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was not associated with OS, but positively associated
with a positive ER or PGR status of the tumors. This
mutual dependence of TWIST1 expression on the pre-
sence of a notable stromal component and an ER-posi-
tive status of the tumor tissue in our and other studies
is in line with the observed prognostic value of TWIST1
in ER-positive disease only. Although our study is a cor-
relative study and cannot reveal causality, it is intriguing
and points to a novel role of TWIST1 in breast cancer.
What is surprising about our results, which associate
high TWIST1 mRNA expression with poor prognosis in
ER-positive breast cancer and with ECM and stromal
content, is the fact that up until now the process of
EMT has been more frequently assigned to ER-negative
cancer and was rarely observed in ER-positive breast
cancer. Also, previously studied breast cancer cell lines
with clear EMT-like features were ER-negative [38].
This left us with an apparent contradiction. We, there-
fore, specifically explored whether markers of EMT pre-
sent on gene expression arrays [11] were associated with
TWIST1 expression. Of the eight markers analyzed, we
found Zinc finger E-box-binding homeobox 1 (ZEB1),
Zinc finger E-box-binding homeobox 2 (ZEB2), Snail2
(SNAI2), Smooth muscle actin, also known as Alpha-
actin-2 (ACTA2) and VIM clearly, positively correlated
with TWIST1 expression (Rs = 0.34, 0.34, 0.35, 0.42 and
0.28, respectively; all P-values <0.001; Additional file 3:
Table S15). This does suggest, in line with the recent
study of Roman-Perez and colleagues [28] that markers
of EMT are co-expressed with TWIST1. However, the
lack of a clear negative association of E-cadherin mRNA
(CDH1) with TWIST1 mRNA expression in our data set
could indicate that EMT may not be fully established.
Alternatively, and more in line with our findings, is that
some markers of EMT, such as Vimentin and Smooth
muscle actin, are also expressed in re-activated stroma
[39]. Therefore, our findings are a starting point for
more functional studies to be certain about TWIST1
possible role in EMT as well as in re-activated stroma in
ER-positive breast cancer.
Conclusions
In summary, we have found that the TWIST1 mRNA
expression level is associated with small tumor size,
invasive lobular carcinoma, stromal-rich tumors and
with PGR and ERBB2 (over)expression. More impor-
tantly, TWIST1 mRNA expression predicts, indepen-
dently of the traditional prognostic factors, poor
prognosis in patients with primary breast cancer. This
association with poor prognosis is particularly observed
in ER-positive disease. For this large retrospective study
that involved 1,427 breast cancer specimens, we made
use of all clinical material available that met the preset
criteria described in Figure 1, thus reaching Level of
Evidence III (LOE-III). To reach LOE-I or -II, a pro-
spective randomized study or pooled meta-analysis is
required. Studying TWIST1 co-expressed genes, we
found that ECM related pathways as well as stromal
content are correlated with TWIST1 mRNA expression
in LNN/ER-positive breast cancer. Functional studies
are, therefore, required to determine the causal relation
between these pathways and the prognostic value of
TWIST1 mRNA expression in ER-positive tumors.
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